Anti-p53 (Human) mAb

WB - 1 ug/mL (chemiluminescence detection system) IP - 2 ug/200 uL of cell extract from 5x106 cells IHC - 2 ug/mL (Heat treatment required for paraffin)

The tumor suppressor p53 controls numerous downstream targets that can result in variable outcomes, including apoptosis, transient growth arrest, and sustained growth arrest or senescence. p53 is induced on DNA damage to prevent gene amplification and preserve genetic stability. Induction of G1 arrest is dependent upon sequence-specific DNA binding and transcriptional activation of p53 target genes such as p21WAF-1/CIP-1. p21 is an inhibitor of cyclin dependent kinase (CDK) and blocks the activity of G1 cyclin-CDK complexes. In cells induction of p21 can block phosphorylation and inactivation of the retinoblastoma protein, thus contributing to G1 arrest. p53 functions to eliminate and inhibit the proliferation of abnormal cells, thereby preventing neoplastic development. Abrogation of the negative growth regulatory functions of p53 occurs in many, perhaps all, human tumours.

1 mg/mL

100 ug IgG in 100 ul volume of PBS containing 50% glycerol, pH 7.2. No preservative iscontained.

Human: 7157 Mouse: 22059

N-terminal synthetic peptide of human p53 (11-25 aa)

This antibody reacts with human p53.

1 year

This antibody was purified from hybridoma (clone DO-1) supernatant using protein A agarose. This hybridoma was established by fusion of mouse myeloma cell SP2 with Balb/c mouse splenocyte immunized with the human p53 N-terminus synthetic peptide (11-25 a.a.).

p53